medigraphic.com

2014, Número 2

<< Anterior Siguiente >>

Revista Cubana de Angiología y Cirugía Vascular 2014; 15 (2)


La lecitin: colesterol aciltransferasa y la enfermedad carotídea

Triana MME

Idioma: Español
Referencias bibliográficas: 44
Paginas:
Archivo PDF: 77.87 Kb.


RESUMEN

Introducción: la lecitin: colesterol aciltransferasa es la enzima encargada de esterificar el colesterol libre extracelular y de participar en la conversión de las subfracciones de lipoproteínas de alta densidad, sin embargo, se desconoce su papel en la enfermedad carotídea.
Objetivo: identificar el papel de la lecitin:colesterol aciltransferasa en la enfermedad carotídea y si puede ser considerado o no como un biomarcador de dicha enfermedad.
Métodos: se revisaron las bases de datos MedLine, PubMed, SciELO, Web of Science y revistas biomédicas cubanas, se seleccionaron artículos de diferentes tipos publicados entre 2009-2013. Los descriptores utilizados fueron: lecitin:colesterol aciltransferasa, dislipidemia, ateroesclerosis carotídea, enfermedad carotídea.
Síntesis de la información: existen evidencias que soporta la relación inversa del colesterol trasportado por las lipoproteínas de alta densidad y la enfermedad carotídea y de la participación de la lecitin:colesterol aciltransferasa en el metabolismo de estas lipoproteínas , sin embargo, las mismas señalan que la lecitin:colesterol aciltransferasa no es necesaria para la protección vascular, y que el efecto "antiaterogénico" de la enzima depende de la calidad de las lipoproteínas mencionadas y del componente genético.
Conclusiones: aún faltan resultados que identifiquen la relación causal entre la lecitin:colesterol aciltransferasa y la enfermedad carotídea, ya que los resultados no son concluyentes, por lo que no se puede considerar a la enzima como un biomarcador predictor de dicha enfermedad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Organización Mundial de la salud (OMS). Las enfermedades no transmisibles, un problema de salud de primer orden para el siglo xxi. En: Estadísticas Sanitarias Mundiales 2012. 2012 [citado 30 Oct 2013]:1-178. Disponible en:http://www.who.int/healthinfo/ES_WHS2012_Full.pdf

  2. Krishnamurthi RV, Feigin VL, Forouzanfar MH, Mensah GA, Connor M, Bennett DA. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010: Findings from the Global Burden of Disease Study 2010. Lancet Global Health. 2013;1(5):e259-e81. doi: 10.1016/S2214-109X(13)70089-5

  3. MINSAP. Dirección Nacional de Registros Médicos y Estadísticas de Salud. Anuario estadístico de salud. 2012 [citado 30 Oct 2013]. Disponible en: http://www.files.sld.cu/dne/files/2013/04/anuario_2012.pdf

  4. Brott TG, Halperin JL, Abbara S, Bacharach JM, Barr JD, Bush RL, et al. Guideline on the management of patients with extracranial carotid and vertebral artery disease: Executive summary. Circulation. 2011;124(4):489-532. doi: 10.1161/CIR.0b013e31820d8d78

  5. Buergo Zuaznábar MA, Fernández Concepción O, Pérez Mellar J, Pando Cabrera A, Lara Fernández G, Lara Rodríguez R, et al. Estenosis carotídea. En: Sánchez Ferrán T, editor. Guía práctica clínica. Enfermedad cerebrovascular. La Habana: Editorial Ciencias Médicas; 2009 [citado 30 Oct 2013]:35-7. Disponible en: http://www.bvs.sld.cu/libros/guia_enf_cerebrovascular/completo.pdf

  6. Taussky P, Hanel RA, Meyer FB. Clinical considerations in the management of asymptomatic carotid artery stenosis. Neurosurgical Focus. 2011 [cited 2013 Oct 31];31(6):1-9. Available from:http://www.thejns.org/doi/pdf/10.3171/2011.9.FOCUS11222

  7. Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ (Buddy), Culebras A. An updated definition of stroke for the 21st Century. Stroke. 2013 [cited 2013 Jul 18];44:2064-89. Available from:http://www.stroke.ahajournals.org/content/44/7/2064.abstract.html doi: 10.1161/STR.0b013e318296aeca

  8. Fernández-Britto JE, Castillo Herrera JA. Aterosclerosis [editorial]. Rev Cubana Invest Bioméd. 2005 [citado 9 Oct 2013];24(3). Disponible en: http://www.scielo.sld.cu/pdf/ibi/v24n3 /ibi01305.pdf

  9. Nakano M, Stephen J, Kramer MCA, Ladich ER, Kolodgie FD, Virmani R. Insights into the natural history of atherosclerosis progression. In: Taylor AJ, Villines TC, editors. Atherosclerosis: Clinical Perspectives Through Imaging. London: Springer-Verlag; 2013. p. 3-12. doi 10.1007/978-1-4471-4288_1

  10. Thompson RC, Allam AH, Lombardi GP, Wann LS, Sutherland ML, Sutherland JD, et al. Atherosclerosis across 4000 years of human history: the Horus study of four ancient populations. Lancet. 2013 [cited 2013 Nov 5]:1-12. Available from: http://www.press.thelancet.com/atherosclerosismummies.pdf

  11. Gupta A, Baradaran H, Schweitzer AD, Kamel H, Pandya A, Delgado D, et al. Carotid plaque MRI and stroke risk. A systematic review and meta-analysis. Stroke. 2013 [cited 2013 Oct 22];44:3071-7. Available from:http://www.stroke.ahajournals.org/content/44/11/3071.full.pdf? doi: 10.1161/?StrokeAHA.113.002551

  12. Berni A, Giuliani A, Tartaglia F, Tromba L, Sgueglia M, Blasi S, et al. Effect of vascular risk factors on increase in carotid and femoral intima-media thickness. Identification of a risk scale. Atherosclerosis. 2011;216:109-14.

  13. Rundek T, Blanton SH, Bartels S, Dong Ch, Raval A, Demmer RT, et al. Traditional risk factors are not major contributors to the variance in carotid intima-media thickness. Stroke. 2013 [cited 2013 Oct 22];44:2101-8. Available from: http://www.stroke.ahajournals.org/content/44/8/2101.abstract.html doi: 10.1161/StrokeAHA.111.000745

  14. Steinberg D. In celebration of the 100th anniversary of the lipid hypothesis of atherosclerosis. J. Lipid Res. 2013;54(11):2946-9.

  15. Reiner Z. New ESC/EAS Guidelines for the management of dyslipidaemias-any controversies behind the consensus? Eur J Cardiovasc Prev Rehabil [editorial]. 2011 [cited 2013 Oct 30];18(5):7247. Available from:http://www.cpr.sagepub.com/content/18/5 /724.full.pdf+html doi: 10.1177/1741826711418946

  16. Navab M, Reddy ST, van Lenten BJ, Alan M. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nature Reviews Cardiol. 2010 [cited 2013 Nov 8];8:222-32. Available from:http://www.nature.com/nrcardio/journal/v8/n4/pdf/nrcardio.2010.222.pdf doi: 10.1038/nrcardio.2010.222

  17. Choudhury RP, Ruparelia N. High-density lipoproteins and cardiovascular disease: the plots thicken. Heart. 2013 [cited 2014 Jan 8];99(4):222-4. Available from: http://www.heart.bmj.com/content/99 /4/222.full.pdf+html

  18. Camont L, Chapman MJ, Kontush A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med. 2011;17(10):594-603.

  19. Glomset JA. The mechanism of the plasma cholesterol esterification reaction: plasma fatty acid transferase. Biochim Biophy Acta. 1962;65:128-35.

  20. Glomset JA. The plasma lecithin: cholesterol acyl transferase reaction. J Lipid Res. 1968;91:155-67.

  21. Vergeer M, Holleboom AG, Kastelein JJP, Kuivenhoven JA. The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? [review]. J Lipid Res. 2010 [cited 2013 Nov 8];51:2058-73. Available from:http://www.jlr.org/content/51/8/2058.full.pdf doi: 10.1194/jlr.R001610

  22. Savel J, Lafitte M, Pucheu Y, Pradeau V, Tabarin A, Couffinhal T. Very low levels of HDL cholesterol and atherosclerosis, a variable relationship a review of LCAT deficiency [review]. Vas Health Risk Management. 2012;8:35761.

  23. Huth K, Kracht J, Schoenborn W, Fuhrmann W. Tangier disease (á-lipoprotein deficiency). Dtsch med Wochenschr. 1970;95(47):2357-61.

  24. Rousset X, Vaisman B, Amar M, Sethi AA, Remaley AT. Lecithin: cholesterol acyltransferase: From biochemistry to role in cardiovascular disease [review]. Curr Opin Endocrinol Diabetes Obes. 2009 [cited 2013 Nov 8];16(2):16371. Available from:: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2910390/pdf/nihms202842.pdf

  25. Holleboom AG, Kuivenhoven JA, Vergeer M, Hovingh GK, van Miert JN, Wareham NJ (†), et al. Plasma levels of lecithin:cholesterol acyltransferase and risk of future coronary artery disease in apparently healthy men and women: a prospective casecontrol analysis nested in the EPIC-Norfolk population study. J Lip Res. 2010 [cited 2013 Nov 8];51:416-21. Available from: http://www.jlr.org/content/51/2/416.full.pdf

  26. Ng DS. The role of lecithin:cholesterol acyltransferase in the modulation of cardiometabolic risks-a clinical update and emerging insights from animal models. Biochim Biophys Acta. 2012;1821(4):654-9. doi: 10.1016/j.bbalip.2011.12.012

  27. Dullaart RP, Perton F, Kappelle PJ, de Vries R, Sluiter WJ, van Tol A. Plasma lecithin: cholesterol acyltransferase activity modifies the inverse relationship of Creactive protein with HDL cholesterol in nondiabetic men. Biochim Biophys Acta. 2010;1801(1):84-8.

  28. Calabresi L, Baldassarre D, Castelnuovo S, Conca P, Bocchi L, Candini C, et al. Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans. Circulation. 2009 [cited 2013 Nov 8];120:628-35.. Available from: http://www.circ.ahajournals.org/content/120/7/628.full.pdf

  29. Calabresi L, Franceschini G. Lecithin:cholesterol acyltransferase, high-density lipoproteins, and atheroprotection in humans. Trends Cardiovasc Med. 2010;20(2)50- 3. doi: 10.1016/j.tcm.2010.03.007

  30. Haase CL, Tybjærg-Hansen A, Qayyum AA, Schou J, Nordestgaard BG, Frikke- Schmidt R. LCAT, HDL cholesterol and ischemic cardiovascular disease: A Mendelian randomization study of HDL cholesterol in 54,500 individuals. Clin Endocrinol Metabol. 2012 [cited 2013 Nov 8];97(2):E248-56. Available from: http://www.jcem.endojournals.org/content/97/2/E248.full.pdf+html

  31. Nakhjavani M, Esteghamati A, Esfahanian F, Ghanei A, Rashidi A, Hashemi S. HbA1c negatively correlates with LCAT activity in type 2 diabetes. Diabetes Res Clin Pract. 2008;81(1):38-41.

  32. Triana Mantilla ME, Fernández Montequín JI, Zapata Vinent JA, Morejón Reinoso O. Lecitin: colesterol aciltransferasa (LCAT) en pacientes con diabetes mellitus de tipo 2 con macroangiopatía diabética de miembros inferiores. Rev Cubana Angiol Cir Vasc. 2011 [citado 9 Nov 2013];11(2). Disponible en: http://www.bvs.sld.cu/revistas/ang/vol_11_2_11/ang04211.htm

  33. Ross Naylor A. Known knowns, known unknowns and unknown unknowns: A 2010 update on carotid artery disease. The Surgeon. 2010;8(2):79-86.

  34. Buergo Zuaznábar MA, Fernández Concepción O, Pérez Mellar J, Pando Cabrera A, Lara Fernández G, Lara Rodríguez R, et al. Dislipidemia. En: Sánchez Ferrán T, editor. Guía práctica clínica. Enfermedad cerebrovascular. La Habana: Editorial Ciencias Médicas; 2009 [citado 30 Oct 2013]:32-4. Disponible en: http://www.bvs.sld.cu/libros/guia_enf_cerebrovascular/completo.pdf

  35. Efthymios D, Avgerinos ED, Liapis CD. Role of lipoproteins in carotid arterial disease. Cap 4. In: Atique Gabriel E, Atique Gabriel S, editors. Inflammatory response in cardiovascular surgery. London: Springer-Verlag; 2013 [cited 2013 Oct 14]:29-36. Available from: http:/www.link.springer.com/chapter/10.1007/978-1-4471-4429- 8_4/fulltext.html

  36. SPARCL Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:54959.

  37. Sillesen H, Amarence P, Hennerici MG. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis. A secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2008;39:3297-300.

  38. Sigala F, Kotsinas A, Savari P. Oxidized LDL in human carotid plaques is related to symptomatic carotid disease and lesion instability. J Vasc Surg. 2010;52:70413.

  39. Wallenfeldt K, Fegerberg B, Wkstrand J. Oxidized low-density lipoprotein in plasma is a prognostic marker of subclinical atherosclerosis development in clinically healthy men. J Intern Med. 2004;256:41320.

  40. Ebinger M, Sievers C, Klotsche J, Schneider HJ, Leonards CO, Pieper L, et al. Triglycerides and stroke risk prediction: lessons from a prospective cohort study in German primary care patients. Front Neur. 2010;1:1-2. doi: 10.3389/fneur.2010.00148

  41. Labreuche J, Deplanque D, Touboul PJ. Association between change in plasma triglyceride levels and risk of stroke and carotid atherosclerosis systematic review and meta-regression analysis. Atherosclerosis. 2010;212:915.

  42. Dobiásová M, Frohlich J. Understanding the mechanism of LCAT reaction may help to explain the high predictive value of LDL/HDL cholesterol ratio. Physiol Res. 1998;47(6):387-97.

  43. Amarenco P, Labreuche J, Touboul PJ. High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis. 2008;196(2):489-96.

  44. Khera AV, Marina Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127-35.




2020     |     www.medigraphic.com